Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress.

vascular repair, endothelial function, cardiovascular anti-aging, atherosclerosis reduction.

Research on Vesugen primarily documents effects related to vascular repair and endothelial function and cardiovascular anti-aging and atherosclerosis reduction. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Vesugen, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

1 provider in the directory currently offers Vesugen.

Across 5 research vendors tracked on PeptideBase, Vesugen has a median price of about $2.75 per mg, typically ranging $2.00–$3.00 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

This systematic review documents the gene expression regulatory properties of short peptides including vesugen (Lys-Glu-Asp from vascular tissue), showing chromatin-binding activity and selective gene modulation in endothelial and vascular smooth muscle cells relevant to vascular aging and endothelial health.